Alvotech (NASDAQ:ALVO) Receives Consensus Rating of “Hold” from Analysts

Shares of Alvotech (NASDAQ:ALVO) have been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.60.

ALVO has been the topic of several recent research reports. Wall Street Zen lowered Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings cut Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Finally, Evercore began coverage on Alvotech in a report on Friday, August 14th. They issued an “outperform” rating on the stock.

Alvotech Price Performance

Shares of ALVO stock opened at $4.43 on Monday. Alvotech has a 52-week low of $2.94 and a 52-week high of $9.25. The stock has a market cap of $1.34 billion, a PE ratio of -7.26 and a beta of 0.18. The business has a 50-day simple moving average of $3.66 and a 200-day simple moving average of $3.73.

Alvotech (NASDAQ:ALVO) last posted its earnings results on Wednesday, August 19th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.06). The company had revenue of $105.77 million for the quarter, compared to analyst estimates of $103.00 million. Alvotech had a negative return on equity of 11.92% and a negative net margin of 36.31%. Sell-side analysts anticipate that Alvotech will post 0.05 earnings per share for the current fiscal year.

Institutional Trading of Alvotech

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Alvotech by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock valued at $35,481,000 after acquiring an additional 114,255 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Alvotech by 1,707.7% during the fourth quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock worth $1,832,000 after buying an additional 337,417 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Alvotech by 88.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock worth $1,331,000 after buying an additional 122,089 shares in the last quarter. Geode Capital Management LLC boosted its position in Alvotech by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock worth $1,308,000 after acquiring an additional 24,667 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in Alvotech during the second quarter worth about $1,782,000.

Key Headlines Impacting Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Alvotech signed a licensing and commercialization agreement with Lotus Pharmaceutical covering proposed biosimilars AVT34, targeting Imfinzi (durvalumab), and AVT87, targeting Hemlibra (emicizumab), in the United States and selected Asian markets. The deal is valued at up to approximately $150 million and expands Alvotech’s potential commercial reach. Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical
• Positive Sentiment: The FDA accepted resubmitted applications for AVT05, a proposed Simponi biosimilar, AVT06, a proposed Eylea biosimilar, and partner Dr. Reddy’s AVT03, targeting Prolia/Xgeva. FDA decisions are expected in the fourth quarter of 2026, creating important approval and launch catalysts. Alvotech Announces Financial Results for the First Half of 2026
• Positive Sentiment: Alvotech said manufacturing returned to planned operating levels near the end of the second quarter after facility improvements constrained output. Management expects stronger product availability and commercial performance in the second half, supported by strong underlying demand in the U.S. and Europe.
• Positive Sentiment: The company projects 2026 revenue of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million. It also strengthened liquidity with approximately $165 million from an equity offering and private placement, plus a new $75 million term loan.
• Neutral Sentiment: Alvotech’s Reykjavik facility received a “Voluntary Action Indicated” classification following an FDA inspection, a favorable compliance outcome but not a product approval.
• Negative Sentiment: First-half adjusted revenue fell 30.8% to $211.9 million, while product and service revenue dropped 48.3%. Adjusted EBITDA declined to $46.9 million, and cash decreased to $142.8 million, highlighting execution and liquidity concerns.
• Negative Sentiment: Second-quarter adjusted loss was $0.11 per share, wider than the expected $0.05 loss, although quarterly revenue of $105.77 million exceeded estimates. The equity financing also creates potential shareholder dilution.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high?quality, cost?effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in?house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).